New Delhi, Jan. 31 -- The Mumbai-based drugmaker said its total sales rose 15.1% year-on-year to Rs.15,469 crore. Total revenue from operations rose 13.4% YoY to Rs.15,520.5 crore, the company said in a regulatory filing.

The company saw steady revenue growth in its branded business in India and emerging markets as well as in global innovative sales, offsetting the decline in sales of Revlimid.

A Bloomberg poll had pegged the drugmaker's revenue to grow to Rs.14,792 crore with profit after tax at Rs.3,035 crore for the quarter.

The pharmaceutical company's earnings before interest, taxes, depreciation, and amortization (Ebitda) for the quarter was Rs.4,948.5 crore, up 23.4%, while the margin was 31.9%, up from 29.3% a year ago.

"Our r...